William Blair reaffirmed a Market Perform rating on Kenvue Inc (NYSE:KVUE), a consumer health company with a market capitalization of $38.69 billion. According to InvestingPro data, the company ...

William Blair reiterated a Market Perform rating on CBOE Holdings (NYSE:CBOE), following the company's latest earnings report. CBOE Holdings reported an adjusted EPS of $2.10, falling short of both ...

William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as the ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...

Equities research analysts at William Blair upped their FY2025 EPS estimates for shares of Modine Manufacturing in a note ...

For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...

The buy now/pay later lender outperformed nearly every analyst estimate in its fiscal Q2 2025 earnings report. CEO Max Levchin said the company is 5 months out from positive GAAP operating income.

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, ...

WJCC Schools last changed the name of one of its schools in 2017. Before it was Laurel Lane Elementary, the elementary school ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...